Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AREV Life Sciences Global Corp C.AREV

Alternate Symbol(s):  AREVF

AREV Life Sciences Global Corp. is a Canada-based biotechnology company engaged in the discovery and commercialization of solutions for health and wellness. It produces ingredients and formulates therapeutic interventions in clinical nutrition, supplements, topicals and rational drug design, based on science. Its nutraceutical product formulations are sold under its BARE and Wright and Well brands. Its BARE and Wright and Well Brands of finished products include natural health products, including cannabidiol (CBD)-infused products such as Canna-Mulsion and NaturVax, an anti-viral supplement; NaturRelax, a natural Sleep Aid; Natur Relief, an anti-inflator and pain relief product, and a line of CBD skincare products and medicinal oils and edibles. Its Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM), with its branded RUTF known as SUS-TAINN (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs), and RESTORE is under development.


CSE:AREV - Post by User

Comment by kash74on Jun 13, 2003 9:57am
155 Views
Post# 6167791

RE: who knows?

RE: who knows?Below is what I cut & pasted from the swiss exchange site... Not sure exactly but it looks like they have about 41 million in their float. ISOTIS SA Address Management Investor Relations 18-20, Avenue de Sévelin CEO: Jacques Essinger IR: Hans Herklots 1004 Lausanne CFO: Pieter Wolters e-mail: public.relations@isotis.com Switzerland Phone: +31 30 229 52 71 Fax: +31 30 228 02 55 www.isotis.com Company Events Last ordinary General Meeting Next ordinary General Meeting Share register closed by 05.06.2003 – – Capital Structure Commercial register Share Capital most recent reporting 41,588,457 CHF -------------------------------------------------------------------------------- Current capital Listed Share Capital most recent reporting 41,588,457 CHF Conditional Capital most recent reporting 3,818,112 CHF 30.12.2002 3,987,640 CHF 12.12.2002 4,000,000 CHF 09.07.2001 737,640 CHF Authorised Capital most recent reporting 14,139,539 CHF 30.12.2002 14,506,236 CHF 12.12.2002 16,577,860 CHF 23.06.2000 2,700,000 CHF Information about the most recent Business Report Last Business Report Accounting Rules Auditors 2001 IAS E&Y Major Shareholders Opting Up / Opting Out Clause: Mandatory offer for sale in accordance with SESTA
Bullboard Posts
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse